Breaking news

Cyprus Seeds And Julie Fisher: Advancing Cyprus’ Innovation Ecosystem

Cyprus Seeds, a pivotal non-profit organisation dedicated to converting academic research into successful startups, recently held a significant meeting with Julie Fisher, the Ambassador of the American Embassy in Cyprus. This discussion underscored the strategic initiatives supporting Cyprus’ burgeoning innovation ecosystem.

Transformative Mentorship and Training

A focal point of the meeting was the introduction of esteemed USA experts Jonathan B. Green, Paul Blackborow, and Linda Plano. Over the past five years, these experts have provided critical mentorship and training, significantly contributing to the development of innovative projects within Cyprus.

Strengthening US-Cyprus Collaboration

The dialogue also explored the role of the US Embassy in further enriching Cyprus’ dynamic innovation landscape. Both parties deliberated on enhancing existing support mechanisms and identifying new opportunities to foster a more robust entrepreneurial environment.

Cyprus Seeds’ Mission and Impact

Cyprus Seeds has been instrumental in nurturing innovative startups by bridging the gap between academic research and commercialisation. Their initiatives have not only fostered entrepreneurial spirit but also positioned Cyprus as a promising hub for innovation in the region.

This meeting marks a milestone in the collaborative efforts to boost Cyprus’ innovation ecosystem. With continued support from international experts and strategic partnerships, Cyprus is poised to become a significant player in the global innovation landscape.

Regeneron Acquires 23andMe in Bankruptcy Auction for $256 Million

Regeneron Pharmaceuticals has strategically acquired 23andMe, a genetic testing company, in a bankruptcy auction for $256 million. The purchase aims to blend pharmaceutical expertise with genetic insights, unlocking a new chapter for scientific exploration.

Regeneron has pledged to adhere to 23andMe’s stringent privacy policies concerning customer data, presenting their intentions to a court-appointed overseer.

The bankruptcy filing in March had raised concerns among lawmakers regarding the privacy of genetic information belonging to over 15 million customers. In response, 23andMe consented to oversight of its data management practices.

Despite the data breach in 2023 and declining demand for their testing kits, 23andMe’s integration into Regeneron aims to drive innovation. Excluding Lemonaid Health, all 23andMe units will merge with Regeneron to continue as an autonomous entity.

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter